Calibre Post Acute: Behavioral Health Failures - NM
Federal inspectors found the facility failed to ensure proper documentation when physicians declined pharmacist recommendations during monthly drug reviews. The violation involved a resident with dementia, insomnia, and major depressive disorder who had been taking the same antidepressant dose for nearly a year.
The resident, identified as R #16, was admitted in October 2024 with multiple conditions requiring careful medication management. The physician prescribed escitalopram oxalate 20 mg once daily for depression on October 17, 2024. The same day, doctors also ordered oxcarbazepine 300 mg twice daily, initially for seizure control but later switched to treat depression in May 2025.
For sleep problems, the resident received trazodone 25 mg once daily, first ordered in November 2024 as a sleep aid and reordered in June 2025 specifically for insomnia.
By July 28, 2025, the consulting pharmacist had concerns. After reviewing the resident's medication regimen, the pharmacist recommended evaluating whether to decrease the escitalopram dose. The resident had been taking the same 20 mg dose since admission nearly ten months earlier.
The physician disagreed with the pharmacist's recommendation and documented "resident with good response, maintain current dose." But the provider failed to include any clinical rationale explaining why a dose reduction should not be attempted.
Federal regulations require physicians to provide medical justification when rejecting pharmacist recommendations during monthly drug regimen reviews. The facility's Director of Nursing confirmed during an October 9 interview that the resident had been taking identical doses of both escitalopram and oxcarbazepine since arrival. She acknowledged the pharmacist recommended a gradual dose reduction for escitalopram and that the provider declined without documenting clinical reasoning.
The Medical Director, interviewed October 14, confirmed that gradual dose reductions for antidepressant medications should be attempted if residents show no signs of depression. Providers are expected to document clinical rationales when they choose not to attempt such reductions, the Medical Director said.
Inspectors found no clinical rationale anywhere in the resident's medical record explaining why the dose reduction should not be conducted. The absence of documentation means facility staff and future providers lack insight into the physician's medical reasoning for maintaining the higher dose.
The deficiency creates risks beyond the individual resident. Without proper documentation of clinical decision-making, residents may continue receiving medications that are no longer necessary. Higher-than-needed doses increase the likelihood of drug interactions when combined with other medications, foods, or beverages.
Antidepressant medications carry particular risks for elderly residents with multiple conditions. Escitalopram can interact with other medications and may cause side effects including drowsiness, dizziness, and increased fall risk. For residents already taking multiple medications for dementia, sleep disorders, and seizure management, unnecessary doses compound these dangers.
The facility's medication management system failed at a critical checkpoint designed to protect residents from overmedication. Monthly pharmacist reviews serve as an independent safety check on prescribing practices, particularly important in nursing homes where residents often take multiple medications with complex interactions.
Federal inspectors classified the violation as having minimal harm or potential for actual harm, affecting some residents. The inspection was conducted following a complaint, suggesting concerns about medication practices may have prompted the federal review.
The resident continues taking the same escitalopram dose that prompted the pharmacist's original concern. Without documented medical reasoning for maintaining the higher dose, questions remain about whether the medication regimen serves the resident's best interests or simply reflects physician resistance to pharmacist oversight.
Calibre Post Acute operates at 2029 Sagecrest Avenue in Las Cruces. The facility must submit a plan of correction addressing how it will ensure physicians document clinical rationales when declining pharmacist recommendations during future drug regimen reviews.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Calibre Post Acute, LLC from 2025-11-18 including all violations, facility responses, and corrective action plans.
Additional Resources
Data source: Official federal inspection data from the Centers for Medicare & Medicaid Services (CMS).
Editorial process: AI-synthesized regulatory data, reviewed for accuracy by our editorial team.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: June 20, 2026 · Our methodology
Calibre Post Acute, LLC in Las Cruces, NM was cited for violations during a health inspection on November 18, 2025.
Federal inspectors found the facility failed to ensure proper documentation when physicians declined pharmacist recommendations during monthly drug reviews.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.